Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,447 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Colon/Rectal Cancer Rectal Cancer Clear all

Conditions: Colorectal Cancer, Breast Cancer
Interventions: Exercise training, Metformin, Educational information; Behavioral · Drug · Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: Colorectal Cancer
Interventions: RXC004, Nivolumab, Denosumab; Drug · Biological
Lead sponsor: Redx Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Santa Rosa, California • Indianapolis, Indiana • Las Vegas, Nevada + 2 more

Conditions: Colorectal Cancer
Interventions: Oral Tablet: Cabozantinib; Drug
Lead sponsor: Academic Thoracic Oncology Medical Investigators Consortium; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 6 more

Conditions: Gastrointestinal Neoplasms, Pancreatic Cancer, Colorectal Cancer, GI Cancers, PDAC - Pancreatic Ductal Adenocarcinoma, PDAC, GI Cancer
Interventions: Not listed
Lead sponsor: Canopy Cancer Collective, LLC; Network
Eligibility: 18 Years and older
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 10
States / cities: San Diego, California • Tampa, Florida • Baltimore, Maryland + 7 more

Conditions: Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
Interventions: Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab; Drug
Lead sponsor: Tempest Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more

Conditions: Metastatic Colorectal Cancer
Interventions: Regorafenib; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 70 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: Rochester, Minnesota • Rochester, New York • Chapel Hill, North Carolina + 1 more

Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
Interventions: ompenaclid, FOLFIRI, Bevacizumab, FOLFOX regimen; Drug
Lead sponsor: Inspirna, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Prescott Valley, Arizona • Tucson, Arizona • Los Angeles, California + 14 more

Conditions: Colorectal Cancer
Interventions: celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 2,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 826
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more

Conditions: Colorectal Cancer
Interventions: tocladesine; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC V8, Stage IV Colorectal Cancer AJCC V8, Stage IV Rectal Cancer AJCC V8
Interventions: Trastuzumab, Trifluridine and Tipiracil Hydrochloride, Tucatinib; Biological · Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: San Diego, California • Durham, North Carolina

Conditions: Colorectal Neoplasms, Neoplasms
Interventions: sunitinib + FOLFOX; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Aurora, Colorado • Nashville, Tennessee • Dallas, Texas

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions: KanSurvive ECHO and Practice Facilitation; Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Westwood, Kansas

Conditions: Colorectal Cancer
Interventions: intervention; Biological
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: imatinib mesylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colon Polyp, Colorectal Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Aerobic Exercise, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Data Collection, Physical Performance Testing, Questionnaire Administration, Sigmoidoscopy, Survey Administration; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer, TNBC, Triple Negative Breast Cancer, Colorectal Cancer, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, NSCLC (Non-small-cell Lung Cancer), Skin Cancer, Melanoma (Skin Cancer)
Interventions: Biopsy; Procedure
Lead sponsor: Elephas; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2038
U.S. locations: 8
States / cities: Fort Smith, Arkansas • Frederick, Maryland • Springfield, Missouri + 4 more

Conditions: Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions: CB-839, Talazoparib; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more

Conditions: Colorectal Cancer
Interventions: Telisotuzumab Adizutecan, Standard of Care; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: cryosurgery; Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 3
States / cities: Hackensack, New Jersey • Rochester, New York • Philadelphia, Pennsylvania

Conditions: Metastatic Colorectal Cancer
Interventions: OSI-906, Everolimus; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Fort Myers, Florida • Nashville, Tennessee

Conditions: Colorectal Cancer
Interventions: GVAX; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Colorectal Cancer
Interventions: Botensilimab, Balstilimab, Standard of Care; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 26
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 18 more

Conditions: Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer, RCC, Clear Cell Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Endometrial Cancer
Interventions: ADU-1805, Pembrolizumab; Drug
Lead sponsor: Sairopa B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Detroit, Michigan • St Louis, Missouri • Charlotte, North Carolina + 5 more

Conditions: Refractory Metastatic Colorectal Cancer, pMMR, MSS
Interventions: RP2, RP3, atezolizumab, bevacizumab; Biological
Lead sponsor: Replimune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • Seattle, Washington

Search by objective public record fields.

Exercise and Metformin in Colorectal and Breast Cancer Survivors

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

The Canopy Cancer Collective Clinical Registry Protocol

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Regorafenib in Metastatic Colorectal Cancer

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors

KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice

First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras

Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer

Testing the Effects of Exercise on Colorectal Cancer Development After Treatment With Pelvic Radiation Therapy for Prostate Cancer

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Cryosurgery in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

Pilot Study of GVAX in Colorectal Cancer Cells

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC